Blue Jet Healthcare Limited · NSE:BLUEJET
Blue Jet Healthcare — Q3 FY25 Earnings Presentation
39 slides from Blue Jet Healthcare's earnings presentation, Jan 29, 2025
Slide 1: Cover letter to stock exchanges
_ BLUE JET HEALTHCARE LIMITED REGISTERED & CORPORATE : 701 & 702, BHUMIRAJ COSTARICA, PLOT 1 &2, SECTOR - 18, SANPADA, NAVI MUMBAI - 400705 T :022- 41840550 / 40037603 F:+912227814204 B LNHE::RJEE T E : sales@bluejethealthcare.com | CIN NO. : U99999MH1968PLC014154 January 29, 2025 To, BSE Limited Na
Slide 2: Investor Presentation Q3 & 9M FY25
@ BLUE JET HEALTHCARE Investor Presentation Q3 &9MFY25
Slide 3: Disclaimer
Disclaimer @ The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Table of Content
@ BLUE JET HEALTHCARE Table of Content 1 Q3 & 9M FY25 Financials 2 Company at a Glance 3 Contrast Media Intermediates 4 High Intensity Sweeteners 5 Pharma Intermediates & API 6 R&D Capabilities 7 Growth Strategy 8 Management and Board of Directors
Slide 5: Q3 & 9M FY25 Financials
- E. 5 by 1 Q3 & 9M FY25 cr ; Fi l Sar << "4 inancials
Slide 6: Q3 & 9M FY25 Earnings Highlights
Q3 & 9M FY25 Earnings Highlights Financial Highlights Q3FY25 v Revenue from operations for Q3 FY25 stood at Rs. 3,184 mn which grew 52.9% QoQ compared to Rs. 2,083 mn in Q2 FY25; up 90.9% on YoY basis compared to Rs. 1,668 mn in Q3 FY24. v Revenue growth is mainly driven by higher sales in Pharmaceu
Slide 7: Q3 & 9M FY25 Earnings Highlights: 9M FY25
Q3 & 9M FY25 Earnings Highlights Financial Highlights 9M FY25 v Revenue from operations for 9M FY25 stood at Rs. 6,895 mn compared to Rs. 5,277 mn in 9M FY24, up 30.7% YoY EBITDA for 9M FY25 came at Rs. 2,378 mn up 35% YoY compared to Rs. 1,762 mn in 9M FY24. EBITDA margin for 9M FY25 was at 34.5% a
Slide 8: Q3 & 9M FY25 Earnings Highlights: Other Highlights
Q3 & 9M FY25 Earnings Highlights Other Highlights v' Company commissioned additional manufacturing block during Q3 FY25 at Ambernath for manufacturing Advance Contrast Media with investment around Rs. 100 mn. Company expects advanced contrast media dispatched to happenin Q4FY25 v" Company have plann
Slide 9: Q3 FY25 Vs Q3 FY24 Financial Performance - Key Metrics
Q3 FY25 Vs Q3 FY24 Financial Performance — Key Metrics © Revenue from Operations** - Growth Trends [RGRYS! Yo¥ , 11.5% 50.1% 90.7% mQ3FY24 mQ3FY25 3,168 1,661 mE = 1,465 1,120 1,249 371 — I - — . Contrast media intermediates High-intensity sweetners Pharma intermediates and API| Total mmmEBITDA —O—E
Slide 10: 9M FY25 Vs 9M FY24 Financial Performance - Key Metrics
9M FY25 Vs 9M FY24 Financial Performance - Key Metrics @ % Revenue from Operations** — Growth Trends S d 1019 Bl 352.200 [l 224.79% g 30.5% :Im: 2520 mOMFY24 m9MFY25 6,857 5,253 3,682 : 3,028 2,663 942 1,038 589 - 39 128 . . I . — Contrast media intermediates High-intensity sweetners Pharma intermed
Slide 11: Profit and Loss Statement
Profit and Loss Statement (J) — Particulars (Rs. Mn) Q3FY25 Q2FY25 QoQ Q3FY24 YoY 9M FY25 9M FY24 YoY Revenue from Operations 3,184 2,083 52.9% 1,668 90.9% 6,895 5,277 30.7% Cost Of Goods Sold 1,444 895 709 3,077 2,284 Gross Profit 1,740 1,187 46.5% 959 81.4% 3,818 2,992 27.6% Gross Margin 54.6% 57.
Slide 12: Financial Performance over the years - Key Metrics
Financial Performance over the years — Key Metrics © Revenue from Operations** — Growth Trends (Rs Mn) CAGR: 10.7% 31.4% 245.4% 12.8% 6,768 7,185 7,084 6,857 4,778 5,070 4,799 3,536 ,028 2,663 1,759 s 412 340 ¥ 133 3 16 55 |128 I =1= o 1| . — Contrast media intermediates High-intensity sweetners Pha
Slide 13: Financials for the last four years
Financials for the last four years @ — Summary Statement of Profit and Loss Summary Statement of Assets and Liabilities I. Assets Revenue from Operations 4,989 6,835 7,210 7,116 6,895 Property, plant and equipment 1,188 1,185 1,282 1,492 2,460 Other Income 89 194] 240 288 340 Other non-current asset
Slide 14: Shareholder Information
Shareholder Information NSE Ticker BLUEJET MF Others BSE Ticker 544009 OtherDlls 12% 10.9% 0.8% Market Cap (INR Cr) 9,790 S A\ % free-float Free-float market cap (INR Cr) 14% 1,371 Cash & Cash Equivalents + Treasury 3313 Investment (INR Mn) ’ Shares Outstanding 17,34,65,425 3MADTV (Shares)* 2,42,079
Slide 15: Company at a Glance
Q Company at a Glance
Slide 16: Our Journey
Our Journey « Established Jet Chemicals « Began manufacturing high- « Entered the X-ray contrast Private Limited with Shahad intensity sweeteners - media sector, with a basic facility (Unit 1) saccharin and its salts building block (5- NIPA) + Commenced semi- automated manufactui . . « Established B
Slide 17: Who we are
Who we are 0 A specialty pharmaceutical and healthcare ingredient and intermediate company, offering niche products with an approach of “Collaboration Development, Manufacturing” to CDMO business.
Slide 18: Blue Jet Healthcare at a glance
Blue Jet Healthcare at a glance © ( 46" ) ( 1,020.90 kL ) r INR7,115.99 mn INR2,292.30 mn Commercialized product reaction capacity across Revenue (FY24) (12.6% EBITDA (FY24) (32.2% portfolio (FY24) 3 facilities (FY24) FY21-24 CAGR) margin) Key metrics ) r INR 3,351.94 mn W ( 26.01% ) ( 21.45% W ( 5-
Slide 19: Overview of our Product Categories
Overview of our Product Categories Contrast Media High Intensity Pharma Intermediates Intermediates Sweeteners & APIs m Contrast media are agents used in medical m High-intensity sweetener business involves m Collaboration with innovator pharmaceutical companies and multi-national generic imaging to
Slide 20: Contrast Media Intermediates
33 Contrast Media Intermediates
Slide 21: Overview of Contrast Media and its growth drivers
Overview of Contrast Media and its growth drivers @ What is contrast media? Types of contrast media B Chemical agents that enhances the contrast of an imaging m X-ray / Computed Tomography (CT) contrast agents: lodine- modality in diagnostic imaging, thereby aiding diagnosis of based contrast media
Slide 22: The global Contrast Media industry is highly concentrated
The global Contrast Media industry is highly concentrated Highly concentrated and dominated by multi-national corporations Player 1 17% Global Forecast US$9.7bn Player 2 By 2029 o Collectively hold ~75% of the global sales of contrast (CAGR: 7.5%) media formulations’ Player 3 27% Either forward inte
Slide 23: High entry barriers for key intermediates' vendors
High entry barriers for key intermediates’ vendors v" More than two decades of experience CAG 0.7% RS v’ 75%+ of exports of a selected contrast media Strict internal standards intermediate (5-Amino-N,N'-bis (2,3- Revenue (INR mn) for product impurity / dihydroxypropyl) isophthalamide) from India’ v
Slide 24: Continue to forward integrate into more advanced intermediates for Contrast Media
Continue to forward integrate into more advanced intermediates for Contrast Media Strong product development and process optimization capabilities underpinned by in-house 5 R&D capabilities Capture larger wallet share with existing customers Focus on molecules with customer interest and strategy in
Slide 25: High Intensity Sweeteners
High Intensity Sweeteners
Slide 26: Blue Jet's positioning in High Intensity Sweetener
Blue Jet’s positioning in High Intensity Sweetener @ Blue Jet's positioni High Intensity Sweeteners product category performance Products ) - K* Adherence to strict internal standards to ensure consistency in quality, performance, | CAG 1%, 6‘3 taste, and impurity profile Revenue (INR mn) Multiple p
Slide 27: Pharma Intermediates & API
5) Pharma Intermediates & API
Slide 28: Trends and features of the Pharma Intermediates and APIs Product Category
Trends and features of the Pharma Intermediates and APIs Product @ Category Key trends in Pharma Intermediates and C market Revenue and capacity utilization predictability (Increased propensity to outsource manufacturing of intermediates & APIs for the CDMO Enables asset light model and ability to f
Slide 29: Overview of Blue Jet's Pharma Intermediates and APIs Product Category
Overview of Blue Jet’s Pharma Intermediates and APIs Product @ Category . . . Pharma Intermediate and APIs Commenced manufacturing pharma intermediates two decades duct cat formance ago, leveraging the customer relationships through high-intensity RrocuchicaresoryaRel {@@} sweetener business G& Key
Slide 30: Leverage long-standing customer relationships to enter adjacencies in pharma intermediate and API
Leverage our long-standing customer relationships to continue @ entering adjacencies in the pharma intermediate and API category A~ A~ , Investigational new drugs and new chemical @ Leverage long-standing relationships with innovator entities (NCEs) companies Develop advanced intermediates for NCEs
Slide 31: R&D Capabilities
os E. Aw by © R&D Capabilities he
Slide 32: Our R&D framework
Our R&D framework @ e - R&D capabilities across Process research Portfolio Process Process scale-up Regulatory filings evaluation development and validation and approvals Analytical research Chemistry research ( ] ( Method ] ( Characterization of ) ( Polymorphism ] (Pharmaceutical saltw ( w ( Hi w L
Slide 33: Sustainability
Sustainability Various initiatives on energy efficiency, renewable energy, and water conservation to reduce carbon footprint Invested in windmills with installed capacity of 3.3MW Created carbon sinks Focus on enhancing through tree plantations energy efficiency Effluent treatment plants with I Mini
Slide 34: Growth Strategy
Z E. 1& by 7 Growth Strategy he
Slide 35: Our strategies
Our strategies (J) ( h Focus on operational efficiency and mitigation of supply chain risks Continue to forward integrate into Continue to investin R&D more advanced intermediates for infrastructure and capabilities Contrast Media Leverage our long-standing Build additional production capacity custo
Slide 36: Management and Board of Directors
S Management and Board of Directors
Slide 37: Experienced and visionary management team backed by independent Board of Directors
Experienced and visionary management team backed by independent - Board of Directors Management team @ Akshay Bansarilal ® Shiven Akshay © Naresh Suryakant Shah @ Ganesh ® Vimalendu Kumar Singh @ Chandrashekar Parenky Arora Arora Executive Director, Head Karuppannan (V.K. Singh) President - Research
Slide 38: Management team and independent Board of Directors (cont'd)
Experienced and visionary management team backed by independent Board of Directors (cont’d) Management team (cont’d) Independent board of directors ®6 Popat B Kedar Sweta Poddar 6 Priyanka Yadav ©® Girish Paman 0 Preeti Gautam & Divya Sameer Executive Director Company Secretary and Independent Direc
Slide 39: Thank you!
Thank you! BLUE JET HEALTHCARE LIMITED INVESTOR RELATIONS AT Registered Office Blue Jet Healthcare Limited 701,702, 7th Floor, Bhumiraj Costarica, Sanjay Sinha, Deputy Chief Financial Officer Sector 18, Sanpada, Navi Mumbai Thane sanjay.sinha@bluejethealthcare.com 400705, Maharashtra, India NSE: BLU